Bris­tol My­ers Squibb turns in pri­or­i­ty re­view vouch­er for sup­ple­men­tal in­di­ca­tion on an old Cel­gene drug

Af­ter turn­ing around Cel­gene’s S1P mod­u­la­tor for a long-await­ed ap­proval in mul­ti­ple scle­ro­sis, Bris­tol My­ers Squibb is now trad­ing in an FDA wild­card to get …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER